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The authors examined 1,615 workers exposed to dioxins in trichlorophenol production in Midland, Michigan, to
determine if there were increased mortality rates from exposure. Historical dioxin levels were estimated by a serum
survey of workers. Vital status was followed from 1942 to 2003, and cause-speciﬁc death rates and trends with
exposure were evaluated. All cancers combined (standardized mortality ratio (SMR) ¼ 1.0, 95% conﬁdence in-
terval (CI): 0.8, 1.1), lung cancers (SMR ¼ 0.7, 95% CI: 0.5, 0.9), and nonmalignant respiratory disease (SMR ¼
0.8, 95% CI: 0.6, 1.0) were at or below expected levels. Observed deaths for leukemia (SMR ¼ 1.9, 95% CI: 1.0,
3.2), non-Hodgkin lymphoma (SMR ¼ 1.3, 95% CI: 0.6, 2.5), diabetes (SMR ¼ 1.1, 95% CI: 0.6, 1.8), and ische-
mic heart disease (SMR ¼ 1.1, 95% CI: 0.9, 1.2) were slightly greater than expected. No trend was observed with
exposure for these causes of death. However, for 4 deaths of soft tissue sarcoma (SMR ¼ 4.1, 95% CI: 1.1, 10.5),
the mortality rates increased with exposure. The small number of deaths and the uncertainty in both diagnosis and
nosology coding make interpretation of this ﬁnding tenuous. With the exception of soft tissue sarcoma, the authors
found little evidence of increased disease risk from exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin.
dioxins; neoplasms; phenols; sarcoma; tetrachlorodibenzodioxin
Abbreviations: CI, conﬁdence interval; IARC, International Agency for Research on Cancer; SMR, standardized mortality ratio;
2,4,5-T, 2,4,5-trichlorophenoxyacetic acid; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCP, 2,4,5-trichlorophenol.
The dioxin, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD),
is classiﬁed by the International Agency for Research on
Cancer (IARC) as a known human carcinogen on the basis
of animal studies and mechanistic information, but the
epidemiology data were judged to be limited (1). Increased
risk of all cancers combined, lung cancer, non-Hodgkin
lymphoma, and soft tissue sarcoma was seen in some epi-
demiology studies butnot in all (1). Some noncancer effects,
such as type 2 diabetes, ischemic heart disease, and non-
malignant respiratory disease, have also been associated
with human TCDD exposures in some studies (2–5).
Some of the highest measured exposures to TCDD occur
among persons exposed to 2,4,5-trichlorophenol (TCP).
This dioxin is an unwanted contaminant in TCP that was
m o s to f t e nu s e dt om a k et h ep e s t icide, 2,4,5-trichlorophe-
noxyacetic acid (2,4,5-T). Because of concerns about
TCDD in 2,4,5-T, the United States terminated its use,
and trade of 2,4,5-Twas restricted internationally. Workers
at The DowChemical Company site in Midland, Michigan,
made TCP from 1942 to 1979 and 2,4,5-T from 1948 to
1982. As reported previously, 12% of these workers de-
veloped chloracne, an acute skin condition, presumably
due to TCDD exposure (6). However, cancer rates were
generally at expected levels (7). Recently, we completed
an extensive dioxin serum evaluation of these workers (8).
In the present study, we used these serum dioxin evalua-
tions to develop historical TCDD exposure estimates for all
TCP and 2,4,5-T workers, updated vital status from the
previous study, and evaluated the risk of cancer and non-
cancer mortality with regard to TCDD exposure levels. To
our knowledge, this is the largest single-plant group of
TCP or 2,4,5-T workers ever studied for the health effects
o fT C D D ,a n dn oo t h e rg r o u ph a sb e e nf o l l o w e ds ol o n g
(1942–2003).
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We identiﬁed 1,615 workers who worked 1 or more days
in a department with potential TCDD exposure. Person-
years at risk were accumulated from January 1, 1942, or
from the date at which a TCP or a 2,4,5-T department
assignment ﬁrst appeared in a worker’s job history, which-
ever was later, and continued to the date of death or through
the end of follow-up, December 31, 2003. We subsequently
refer to this group of 1,615 as the TCP workers. Death
certiﬁcates were obtained from the states in which the em-
ployees died and coded to the International Classiﬁcation of
Diseases revision in effect at the time of death. This study
conduct was pursuant to review and oversight by a human
subjects review board in Midland, Michigan.
A serum evaluation of a 17% sample (280 of 1,615) of the
study population indicated that TCDD levels were greater
than those of unexposed workers or the background levels in
the community (8). We used these serum dioxin levels to
produce a model to estimate historical exposure levels of
TCDD for all the 1,615 workers, as described in detail else-
where (9). Brieﬂy, we used a qualitative exposure charac-
terization from an earlier study to group all TCP-exposed
jobs into 1 of 4 similarly exposed groups (10). This quali-
tative exposure assessment was derived from detailed work
history, industrial hygiene monitoring, and the presence of
chloracne cases among groups of workers. We selected
a sample of workers on the basis of time spent in each group,
drew blood from 280 former TCP workers, and measured
the levels of dioxins, furans, and polychlorinated biphenyls
(8). We used a simple 1-compartment, ﬁrst-order pharma-
cokinetic model and assumed elimination rates as previ-
ously estimated from a worker population (11). We
integrated the pharmacokinetic model with the work history
information detailing dates of assignment to jobs in each of
the 4 groups and determined the average TCDD dose asso-
ciated with jobs in each group, after accounting for the
presence of background exposures estimated from the re-
sidual serum TCDD concentration in the sampled individu-
als. A pharmacokinetic model applied job-speciﬁc dose
rates from the sampled workers to the work history of each
member of the entire cohort to estimate time-dependent
serum concentration proﬁles for TCDD. The area under
the curve for TCDD was used to represent the cumulative
workplace dioxin exposure above background at any point
in a worker’s career.
One hundred and ninety-six of the 1,615 TCP workers
also had potential exposure to pentachlorophenol. Although
pentachlorophenol does contain dioxin contaminants, sig-
niﬁcant levels of TCDD are not found in pentachlorophenol
(1). We examined the TCP workers with and without the 196
pentachlorophenol workers.
Standardized mortality ratios for cause-speciﬁc mortality
of the workers compared with the US population were
calculated by using the OCMAP program (12). We also
examined exposure-response trends in disease through a
proportional hazards regression model with SAS PROC
PHREG (SAS Institute, Inc., Cary, North Carolina), treating
TCDD as a continuous linear predictor (13). For each model
parameter, the procedure calculates a regression coefﬁcient
and standard error, a Wald chi-square statistic, a P value for
the test with coefﬁcient 0, and a hazard ratio and 95% con-
ﬁdence interval. Chi-square and P values are also provided
for tests of linear hypotheses of parameter estimates. The
time variable for the proportional hazards model was age,
and all models included hire year and year of birth. Expo-
sure was treated as a time-dependent variable. The causes of
death for exposure-response analyses were selected on the
basis of ﬁndings from previous studies or if the standardized
mortality ratios were high in our study (3, 5, 14–18).
RESULTS
Vital status follow-up was complete for all but 2 workers
(6.6 person-years lost to follow-up), and we obtained 661
death certiﬁcates for the 662 known decedents. The mean
age at start of follow-up was 29.6 years, and the mean du-
ration of follow-up was 36.4 years. The cumulative expo-
sures in our study ranged from 0.0002 to 112.3 parts per
billion-years with a mean of 3.9.
There were 177 cancers (SMR ¼ 1.0, 95% conﬁdence
interval (CI): 0.8, 1.1) among the 1,615 TCP workers shown
in Table 1. Among the causes of death of a priori interest,
there were fewer deaths than expected from lung cancers
(SMR ¼ 0.7, 95% CI: 0.5, 0.9) and nonmalignant respira-
tory disease (SMR ¼ 0.8, 95% CI: 0.6, 1.0). There were
more deaths from non-Hodgkin lymphoma (SMR ¼ 1.3,
95% CI: 0.6, 2.5), leukemia (SMR ¼ 1.9, 95% CI:
1.0, 3.2), soft tissue sarcoma (SMR ¼ 4.1, 95% CI: 1.1,
10.5), diabetes (SMR ¼ 1.1, 95% CI: 0.6, 1.8), and ischemic
heart disease (SMR ¼ 1.1, 95% CI: 0.9, 1.2) than expected.
Table 1 also presents the standardized mortality ratios for
trichlorophenolworkersexcludingthe196workerswhoalso
had exposure to pentachlorophenol. There were 567 deaths
(SMR ¼ 0.9, 95% CI: 0.8, 1.0) among these 1,419 workers.
The standardized mortality ratios for all causes of death are
very similar to those for all TCP workers, so the subset is not
further described separately.
Table 2 lists the hazard ratio estimates using the propor-
tional hazards model for a 1-part per billion-year increase in
cumulative exposure of TCDD for diseases of a priori in-
terest. None of the causes of death examined showed a sig-
niﬁcant trend with cumulative TCDD except soft tissue
sarcoma. The hazard ratio estimates for soft tissue sarcoma
for a 1-part per billion-year increase is 1.060 (95% CI:
1.017, 1.106).
DISCUSSION
Among the strengths of this study are the relative size, the
length of follow-up, and the technology used to assess ex-
posures. Our cohort is the largest collection of TCP workers
from a single plant ever studied for the health effects of
TCDD, and our study has an exceptionally long follow-up
period, 62 years, with an average individual follow-up of
over 36 years. Exposure measures were derived from the
most extensive serum dioxin evaluation ever conducted on
industrial workers, coupled with complete work history re-
cords and detailed industrial hygiene monitoring data, and
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Am J Epidemiol 2009;170:501–506Table 1. Standardized Mortality Ratios and 95% Conﬁdence Intervals for SelectedCauses of Death for Workers With Trichlorophenol Exposure,
Midland, Michigan, 1942–2003
Death Category
(ICD-10 Code)
All Trichlorophenol Workers
Trichlorophenol Workers Excluding
196 Workers Who Also Had
Pentachlorophenol Exposure
No. of
Deaths
Standardized
Mortality Ratio
95% Conﬁdence
Interval
No. of
Deaths
Standardized
Mortality Ratio
95% Conﬁdence
Interval
All causes (A00–Y89) 662 0.9 0.9, 1.0 567 0.9 0.8, 1.0
All cancers (C00–C97) 177 1.0 0.8, 1.1 154 0.9 0.8, 1.1
Esophagus (C15) 5 1.0 0.3, 2.2 5 1.1 0.4, 2.5
Stomach (C16) 8 1.4 0.6, 2.7 7 1.4 0.6, 2.8
Large intestine (C18) 18 1.2 0.7, 1.8 15 1.1 0.6, 1.8
Rectum (C20, C21) 2 0.6 0.1, 2.1 2 0.7 0.1, 2.4
Biliary passages
and liver (C22, C24)
2 0.5 0.1, 1.6 2 0.5 0.1, 1.9
Pancreas (C25) 6 0.7 0.2, 1.4 4 0.5 0.1, 1.3
Other digestive (C17,
C19, C23, C26, C48)
2 1.4 0.2, 5.1 2 1.6 0.2, 5.8
Larynx (C32) 3 1.3 0.3, 3.9 3 1.5 0.3, 4.4
Bronchus, trachea,
lung (C33, C34)
46 0.7 0.5, 0.9 41 0.7 0.5, 1.0
All other respiratory
(C30, C31, C37–C39)
1 1.6 0.0, 9.1 1 1.8 0.0, 10.3
Prostate (C61) 21 1.4 0.9, 2.2 20 1.5 0.9, 2.4
Testes and other
male genital (C60, C62, C63)
1 1.6 0.0, 8.9 1 1.8 0.0, 10.1
Kidney (C64, C65) 2 0.4 0.1, 1.5 2 0.5 0.1, 1.7
Bladder and other
urinary (C66–C68)
6 1.2 0.5, 2.7 5 1.2 0.4, 2.7
Malignant melanoma (C43) 2 0.6 0.1, 2.3 1 0.4 0.0, 2.0
Central nervous
system (C70–C72)
3 0.6 0.1, 1.7 2 0.4 0.1, 1.6
Hodgkin disease (C81) 2 1.8 0.2, 6.4 2 2.0 0.2, 2.3
Non-Hodgkin lymphoma
a (C81) 9 1.3 0.6, 2.5 8 1.3 0.6, 2.6
Leukemia and
aleukemia (C91–C95)
13 1.9 1.0, 3.2 12 1.9 1.0, 3.4
Other lymphopoietic (C88, C90, C96) 2 0.6 0.1, 2.3 2 0.7 0.1, 2.6
Soft tissue sarcoma (C49) 4 4.1 1.1, 10.5 3 3.5 0.7, 10.2
Diabetes mellitus (E10–E14) 16 1.1 0.6, 1.8 15 1.2 0.7, 1.9
Cerebrovascular disease (I60–I69) 37 1.0 0.7, 1.4 29 0.9 0.6, 1.3
Ischemic heart disease (I20–I25) 218 1.1 0.9, 1.2 186 1.0 0.9, 1.2
Nonmalignant respiratory
disease (J00–J99)
44 0.8 0.6, 1.0 39 0.8 0.5, 1.1
Ulcer of stomach and
duodenum (K25–K27)
2 0.8 0.1, 2.9 1 0.5 0.0, 2.5
Cirrhosis of liver (K70–K74) 6 0.4 0.1, 0.8 6 0.4 0.2, 0.9
Accidents (V01–X59) 35 0.9 0.6, 1.3 29 0.9 0.6, 1.2
Missing
certiﬁcates,
no.
Persons,
no.
Person-years,
no.
Missing
certiﬁcates,
no.
Persons,
no.
Person-years,
no.
1 1,615 58,743 1 1,419 51,986
Abbreviation: ICD-10, International Classiﬁcation of Diseases, Tenth Revision.
a Comparison rates available only since 1960.
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study population (6).
The 2 studies that exceed ours in size are compiled groups
from multicentric studies and are not likely to be homoge-
neous with regard to exposures and other potential disease
determinants; hence, they are subject to exposure misclas-
siﬁcation and confounding. The exposure measures used in
these investigations are either duration of employment (17)
or serum dioxin estimates drawn from 2 plants of 8 in the
study (3). Though less likely in our study, some exposure
misclassiﬁcation may have been introduced through group-
ing workers into similar groups or through the assumptions
used in the pharmacokinetic modeling of TCDD uptake and
elimination. An additional limitation is that our study group
is still not large enough to provide precise mortality risk
estimates for uncommon diseases. In several instances, such
as for non-Hodgkin lymphoma, we cannot rule out the pos-
sibility of a small risk from exposure. As an alternative to
mortality, we considered incidence analysis as a means to
increase the power of detecting less common diseases. For
instance, the background incidence of soft tissue sarcoma is
almost double the mortality rate, and incidence data are
known to be more accurate than death certiﬁcate diagnoses.
However, because cancer registries are limited both geo-
graphically and temporally, accurate disease ascertainment
in this cohort is not possible. The Michigan cancer registry,
for example, has been in operation for only the last 24 years
of our 63-year follow-up period.
Four deaths from soft tissue sarcoma (SMR ¼ 4.1, 95%
CI: 1.1, 10.5) were observed in our study. Soft tissue
sarcoma is the cause of death initially associated with
TCDD exposure (19–21). However, subsequent studies have
not consistently found an excess for this cause. Soft tissue
sarcoma is a somewhat arbitrary collection of tumors that,
when coded from death certiﬁcates, often are subject to in-
advertent misclassiﬁcation (22). The coding rules for the
International Classiﬁcation of Diseases combine consider-
ations of morphology, behavior, and anatomic site of the
tumor origin, so that soft tissue sarcomas that originate in
a visceral organ are coded to that organ and not to the soft
tissue sarcoma category. Moreover, the accuracy of the
death certiﬁcate for soft tissue sarcoma diagnoses is poor
(22, 23). Of the 4 deaths in our study that speciﬁed soft
tissue sarcoma as the underlying cause of death, 3 were
described as malignant ﬁbrous histiocytomas, and the fourth
as an angiosarcoma of the scalp. Two of these deaths were
cited in previous studies (7, 24), where it was reported that
tissue examinations revealed 1 of these deaths to be a renal
clear cell carcinoma and, thus, not in the soft tissue sarcoma
category. This death had the highest TCDD exposure among
the soft tissue sarcoma deaths. Although it is unlikely that
misclassiﬁcation of this disease occurs differentially in the
exposed and the referent populations, reclassiﬁcation of 1
or 2 deaths could dramatically impact risk estimates and
exposure-response trends for uncommon diseases. The
small number of soft tissue sarcomas in our study, the po-
tential for misdiagnosis, the uncertainty of nosology coding,
the diversity of histologic types, and the lack of similar
ﬁndings in other studies argue for caution in assessing eti-
ology for this tumor category (5, 14, 22, 25–27).
In contrast to 3 similar studies (3, 14, 25), our study
found no overall increase in lung cancer risk among work-
ers exposed to relatively high levels of TCDD. Compared
with lung cancer rates in the US population, those in TCP
workers were lower overall and displayed a decreasing
trend with exposure. The lower standardized mortality
ratio estimates could be due to reduced smoking among
the TCP workers compared with the US population, which
is also consistent with the observed lower risk for nonma-
lignant respiratory disease. However, it is less likely that
the decreasing trends with exposure seen for both causes of
death in the internal analyses could be attributed to differ-
ential smoking behavior. As with most occupational cohort
studies, there was no assessment of smoking behavior for
study subjects, so adjustment for potential confounding
was not possible. However, given the low rates of lung
cancer among these workers, the lack of an exposure re-
sponse, and the relative homogeneity of the workers, it
seems unlikely that confounding from smoking could be
m a s k i n ga ne f f e c t .
Table 2. Hazard Ratio Estimates With 95% Conﬁdence Intervals for a 1 Part Per Billion-Year
Increase in Cumulative Exposure to 2,3,7,8-Tertachlorodiphenyl-p-dioxin Using a Proportional
Hazards Model, Midland, Michigan, 1942–2003
Cause of Death Parameter
Estimate
a
P Value
for Chi-Square
Hazard
Ratio
95% Conﬁdence
Interval
All cancers 0.00161 0.7762 1.002 0.991, 1.013
Lung  0.00173 0.8853 0.998 0.975, 1.022
Prostate 0.01294 0.2950 1.013 0.989, 1.038
Leukemia and aleukemia  0.12822 0.3384 0.880 0.677, 1.144
Non-Hodgkin lymphoma 0.01081 0.6773 1.011 0.961, 1.064
Soft tissue sarcoma 0.05872 0.0060 1.060 1.017, 1.106
Diabetes 0.00435 0.7864 1.004 0.973, 1.036
Ischemic heart diseases  0.00106 0.8402 0.999 0.989, 1.009
Nonmalignant respiratory disease  0.00357 0.7562 0.996 0.974, 1.019
a The time variable was age, and all models included hire year and birth year.
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slightly greater than expected in our study. Although
non-Hodgkin lymphoma deaths have been greater than
expected in some studies of workers exposed to dioxin,
leukemia deaths were atexpected levels in these same studies
(3, 26). We found no association with exposure for either of
these causes of death. Ischemic heart disease rates were
slightlygreaterthanexpectedinourstudy,whichisconsistent
withsomestudies(3,26)butnotothers(14,28).Likewise,we
observedslightlymorediabetesdeathsthanexpected,whichis
consistent with 1 large study (3), yet neither study found an
increaseinriskwithexposuretoTCDD.Occupationalstudies
often ﬁnd decreased rates of heart disease and diabetes as
a result of the healthy worker effect, sowe should be cautious
in our interpretation. Regardless, there is little evidence of
an association with TCDD exposure for non-Hodgkin
lymphoma, leukemia, ischemic heart disease, or diabetes.
Of the 4 studies of industrial workers that used serum
dioxin evaluations to estimate exposures, each found in-
creased total cancer rates associated with increasing expo-
sure to TCDD (14, 25, 26, 29, 30). However,our studyfound
cancer rates at levels slightly less than expected and no trend
with exposure. It is unlikely that the exposure levels in our
study were lower than in the others, since such a large por-
tion of our study group developed chloracne. Considering
individual cancer sites, there seems to be no consistency
across the 4 previous studies. For instance, exposure re-
sponses were reported for lung cancer and digestive cancer
in the study of Ott and Zober (14), lung cancer in the studies
of Steenland et al. (3) and Hooiveld et al. (26), and no
speciﬁc cancer sites in the study of Flesch-Janys et al.
(25). In our study, we found a trend with soft tissue sarcoma
but no trend with the other cancers or all cancer combined.
A recent IARC evaluation posited a ‘‘pleuripotential’’
mode of action manifested as a causal relation between
TCDD and all cancers combined in the absence of a consis-
tent ﬁnding for any speciﬁc cancer site (1). Such an associ-
ation has no precedent in epidemiology studies (31). Some
have argued that dioxin may be a late-stage carcinogen pro-
ducing excess cancers at many organ sites (32). Although
this hypothesis may explain the increased risk with all can-
cers combined, it does not explain the lack of consistency of
speciﬁc cancer site ﬁndings across studies, because all late-
stage carcinogens cause one or more speciﬁc cancers (31).
Others have speculated that exposures other than dioxins at
the various plants in the studies have resulted in different
cancer risks at individual plants contributing to increased
cancer risk overall (31, 33). This hypothesis has only been
rarely studied in industrial workers exposed to TCDD.
The pleuripotential cancer theory of TCDD has led in part
to the IARC classiﬁcation of TCDD as a known human
carcinogen (1). New studies and study updates since this
evaluation have been judged to be either supportive or not
supportive of this IARC assessment (31, 32). In our study,
we ﬁnd cancer rates at expected levels and no trend with
exposure, an outcome in common with those of 2 recent
studies with high TCDD exposure (5, 27). These new re-
search ﬁndings question the IARC 1997 classiﬁcation of
TCDD as a known human carcinogen based on an excess
of all cancers combined.
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